# Cellectricon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellectricon

- Industry: Biotechnology
- Headquarters: Molndal, Sweden
- Website: www.cellectricon.com
- Total disclosed funding: $7M
- Latest round: Series B (May 26, 2004)
- Investors on record: 3

## About

Cellectricon AB is a biotechnology firm specializing in advanced in vitro research services that accelerate neuroscience drug discovery through innovative technologies.Cellectricon AB, headquartered in Molndal, Sweden, provides research services that focus on neuroscience drug discovery. Founded by individuals with a robust background in biotechnology, they have undergone strategic pivots to enhance their offerings in the biopharmaceutical sector. The company has secured a total of SEK 53.0 mn in funding through various rounds, with the most recent being a Grant of SEK 2.3 mn from VINNOVA in September 2006, marking their fifth investment deal. Currently, the CEO is Mattias Karlsson.Cellectricon specializes in providing advanced in vitro research services aimed at accelerating neuroscience drug discovery. Their core product offerings include service modules for various neurological conditions, such as Peripheral Neuropathies, Neurodegeneration, Neuroplasticity, and Neuroinflammation. These services leverage innovative technologies and biologically relevant systems to identify new drug targets and optimize lead compounds for pharmaceuticals. Cellectricon primarily serves clients in the biopharmaceutical industry, including research institutions and companies focused on neurological drug development. Their products are marketed across multiple geographical regions, including North America, Europe, and parts of Asia, catering to a diverse client base engaged in neuroscience research.Cellectricon's revenue structure is primarily based on collaborative research services provided to their clients, which include major pharmaceutical companies and biotech firms. In 2023, the company reported a revenue of SEK 2,777,073.30 and an EBITDA of SEK 846,536.60. Transactions typically involve project-based agreements where clients engage Cellectricon for specific research initiatives tied to their drug development pipelines. The services are structured as direct contracts, often with predefined milestones and deliverables, facilitating ongoing partnerships. Cellectricon emphasizes collaboration and scientific exchange, which enhances their value proposition in the competitive landscape of neuroscience research services.Cellectricon is focused on expanding its product offerings and entering new geographical markets. The recent funding of SEK 2.3 mn from VINNOVA is anticipated to support the development of innovative new products aimed at enhancing their service modules. The company plans to strengthen its presence in existing markets while exploring opportunities in emerging regions over the next few years, leveraging these resources to build on their portfolio and service capabilities.

## Funding rounds

- Series B, May 26, 2004, $7M — InnovationsKapital, KI Management, Patricia Industries

## Investors

- InnovationsKapital (https://capitalatlas.ai/funds/innovationskapital) — Series B
- KI Management (https://capitalatlas.ai/funds/ki-management) — Series B
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series B